AstraZeneca/Oxford Intranasal COVID-19 Vaccine Fails in Phase I Clinical Trial
AstraZeneca
Biopharmaceutical Manufacturer
University of Oxford
The University of Oxford (commonly referred to as "Oxford") is a public research university located in Oxford, England. Operating under a collegiate federal system, it is collectively known with the University of Cambridge as "Oxbridge." Together with the University of Cambridge, University College London, Imperial College London, and the London School of Economics and Political Science, it forms the "G5 Super Elite Universities."While the exact founding date of the University of Oxford is lost to history, archival records clearly indicate that teaching commenced as early as 1096. The university experienced rapid development after receiving substantial support from the English royal family in 1167. It is the oldest university in the English-speaking world and the second-oldest surviving higher education institution globally. The University of Oxford holds prestigious academic standing and extensive influence in fields such as mathematics, physics, medicine, law, and business, and is widely recognized as one of the world’s leading higher education institutions. In the 2017–18 Times Higher Education World University Rankings, Oxford ranked first worldwide; in the Academic Ranking of World Universities (ARWU), it ranked seventh globally.On December 18, 2018, the "2018 World Brand 500" list, compiled by the World Brand Lab, was released, with the University of Oxford ranked 99th.
According to foreign media reports, the AstraZeneca/Oxford University nasal spray COVID-19 vaccine showed poor results in early studies. The findings indicated that the vaccine only triggered an antibody response in "a small number of participants," andImmunityThe response is weaker than the standard vaccine.
This is a single-center, open-label, Phase I study conducted in the UK to evaluate the safety and immunogenicity of ChAdOx1 nCoV-19 administered intranasally in patients, with a total of 30 subjects who have not been vaccinated against COVID-19 and 12 subjects who received this intranasal vaccine as a booster.
The results showed that the vaccine demonstrated acceptable tolerability but elicited a "weak and inconsistent" immune response in participants, which was insufficient to support further development of the intranasal COVID-19 vaccine.
Previously, the adenovirus vector COVID-19 vaccine Vaxzevria, co-developed by the University of Oxford and AstraZeneca, was launched in the UK in January 2021. It uses a replication-deficient chimpanzee adenovirus ChAdOx1 as a vector, containing the full-length spike protein of SARS-CoV-2 and a TPA leader sequence. In 2021, this vaccine generated $3.917 billion in revenue for AstraZeneca.